> See specialized channels
Medical Devices & Diagnostics
> See specialized channels
> See specialized channels

  Join us

  Follow us on Twitter   Join our LinkedIn Group   Our Blog

Biotech News App
Provides access to the latest biotech press releases ...more

Android_Logo App Store RIM_Logo_small

Media Partnership:
Want to have your RSS feed integrated on our website? Contact us
RSS Feeds RSS Feeds
JoomlaWatch Stats 1.2.9 by Matej Koval
For Editors
Sign up for press releases
For Companies
Sign up for our newsletter

CoCo Therapeutics Ltd Announces Appointment of Steve Butcher as Chief Operating Officer

| Print |
Thursday, 07 March 2013 14:00 (UTC + 1)

CoCo Therapeutics logo

London UK, March 7, 2013 / B3C newswire / - CoCo Therapeutics Ltd, a newly formed biotechnology company, today announced the appointment of Dr Steve Butcher as Chief Operating Officer. Dr Butcher was a founder and Scientific Director of the Fujisawa Institute of Neuroscience, before holding management positions of increasing responsibility at Pharmacia AB. More recently he held executive positions in a number of biotechnology companies, including CSO at BioImage A/S and COO at TopoTarget A/S.

Raj Parekh, General Partner at Advent Venture Partners and the Chairman of CoCo said "We are pleased that an individual of Steve’s calibre is now leading the programmes at CoCo Therapeutics. The Board looks forward to working closely with Steve to evaluate RAR-alpha agonists in Alzheimer's disease."

Alzheimer’s disease (AD) is the most common cause of dementia, affecting around 5.3 million people in the US, 417,000 people in the UK and many millions of others worldwide. It is estimated that this incidence will more than double by 2050, should current trends continue.

About CoCo Therapeutics
CoCo Therapeutics is a UK biotechnology company focussed on the discovery of new drugs for the treatment of Alzheimer’s disease. The company’s programmes are based on the recent scientific discoveries from the laboratory of Professor Jonathan Corcoran at King’s College London, made during research funded by the Wellcome Trust. This research has implicated RAR-alpha, a novel target, in Alzheimer’s disease.

About Advent Venture Partners
Advent Life Sciences is the dedicated Life Sciences team at Advent Venture Partners, one of Europe’s best established venture capital firms.  Advent Life Sciences invests predominantly in early-stage and growth equity life sciences companies in the UK, Europe and the US.  It will back companies that have a first- or best-in-class approach in a range of sectors within life sciences, including new drug discovery, enabling technologies, med-tech and diagnostics.
Advent Life Sciences is a leader in European life sciences venture capital.  Its investments include:  PowderMed, a therapeutic DNA vaccine company sold to Pfizer; Thiakis, an obesity treatment company acquired by Wyeth Pharmaceuticals; Respivert, a drug discovery company focused on respiratory diseases that was acquired by Johnson & Johnson; EUSA Pharma, a transatlantic speciality pharmaceutical company acquired by Jazz Pharmaceuticals; Avila Therapeutics, a biotechnology company developing targeted covalent drugs acquired by Celgene Corporation, Micromet, a biotechnology company acquired by Amgen and Algeta (OSE: ALGETA), an oncology company developing treatments for bone metastases and disseminated tumours.

For enquiries, please contact
Steve Butcher
Chief Operating Officer
CoCo Therapeutics Ltd
T: +44 20 7932 2100
E: This e-mail address is being protected from spambots. You need JavaScript enabled to view it